Results of a clinical phase Ⅱ trial of whole breast irradiation with a hypofractionated simultaneous integrated boost to the tumor bed after breast-conserving surgery for early breast cancer
Department of Radiation Oncology (Yang ZZ,Yu XL,Mei X,Ma JL,Pan ZQ,Chen XX,Zhang L,Guo XM),Department of Breast Surgery (Wu J,Shao ZM),Fudan University Cancer Center,Shanghai 200032,China;Department of Radiation Oncology,Affiliated Ruijin Hospital of Shanghai Jiao Tong University,Shanghai 200025,China (Chen JY)
Abstract：Objective To report the clinical results of whole breast irradiation with a hypofractionated simultaneous integrated boost to the tumor bed after breast-conserving surgery for early breast cancer. Methods From October 2010 to April 2013, 200 patients with early breast cancer who were admitted to our center and treated with breast-conserving surgery were prospectively enrolled as subjects. All patients received inversely intensity-modulated whole breast irradiation with a dose of 45 Gy in 25 fractions and a simultaneous integrated boost to the tumor bed with a dose of 0.6 Gy/Fx (a total dose of 60 Gy in 25 fractions) five times a week. Logistic regression analysis was used to examine the predictive factors for the occurrence of grade 2 radiation skin reactions. Results All patients completed the radiotherapy treatment. The mean planning target volumes (PTVs) of diseased breast and tumor bed were 529.2 cc and 92.9 cc, respectively. The mean V20 of the ipsilateral lung was 17.2%, and the mean dose for the heart was 531 cGy in patients with left breast cancer. According to the Common Terminology Criteria for Adverse Events, version 3.0, the incidence rates of grade 0, 1, and 2 radiation dermatitis in all patients were 8%, 63%, and 29%, respectively. In all patients, 10.5% had moist desquamation. The multivariate analysis revealed that the PTVs of the tumor bed and whole breast were predictive factors for grade 2 dermatitis. In 185 patients who did self-evaluation of breast cosmetic outcome, 50(87.1%) were rated as excellent, 111(60.0%) as good, and 24(12.9%) as fair. The median follow-up time was 38 months (2-56 months), and the 3-year local control rate was 98.7%. Conclusions The whole breast irradiation with a hypofractionated simultaneous integrated boost to the tumor bed achieves satisfactory acute skin toxicity profile and cosmetic outcome. A 3-year follow-up reveals a good local control rate.
. Results of a clinical phase Ⅱ trial of whole breast irradiation with a hypofractionated simultaneous integrated boost to the tumor bed after breast-conserving surgery for early breast cancer[J]. Chinese Journal of Radiation Oncology, 2016, 25(7): 703-707.
[1]Veronesi U,Cascinelli N,Mariani L,et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J].N Engl J Med,2002,347(16):1227-1232.DOI:10.1056/ NEJMoa020989 [2]Fisher B,Anderson S,Bryant J,et al. Twenty-year follow-up of a randomized trial comparing total mastectomy,lumpectomy,and lumpectomy plus irradiation for the treatment of invasive breast cancer[J].N Engl J Med,2002,347(16):1233-1241.DOI:10.1056/NEJMoa022152 [3]Singla R,King S,Albuquerque K,et al. Simultaneous- integrated boost intensity-modulated radiation therapy (SIB-IMRT) in the treatment of early-stage left-sided breast carcinoma[J].Med Dosim,2006,31(3):190-196.DOI:10.1016/j.meddos.2005.11.001 [4]van der Laan HP,Dolsma WV,Maduro JH,et al. Three- dimensional conformal simultaneously integrated boost technique for breast-conserving radiotherapy[J].Int J Radiat Oncol Biol Phys,2007,68(4):1018-1023.DOI:10.1016/ j.ijrobp.2007.01.037 [5]Vicini FA,Sharpe M,Kestin L,et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy[J].Int J Radiat Oncol Biol Phys,2002,54(5):1336-1344.DOI:10.1016/S0360-3016(02)03746-X [6]McDonald MW,Godette KD,Butker EK,et al. Long-term outcomes of IMRT for breast cancer:a single-institution cohort analysis[J].Int J Radiat Oncol Biol Phys,2008,72(4):1031-1040.DOI:10.1016/j.ijrobp.2008.02.053 [7]Freedman GM,Anderson PR,Li JS,et al. Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer[J].Am J Clin Oncol,2006,29(1):66-70.DOI:10.1097/01.coc.0000197661.09628.03 [8]Pignol JP,Olivotto I,Rakovitch E,et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis[J].J Clin Oncol,2008,26(13):2085-2092.DOI:10.1200/JCO.2007.15.2488 [9]McDonald MW,Godette KD,Whitaker DJ,et al. Three-year outcomes of breast intensity-modulated radiation therapy with simultaneous integrated boost[J].Int J Radiat Oncol Biol Phys,2010,77(2):523-530.DOI:10.1016/j.ijrobp.2009.05.042 [10]彭冉,王淑莲,金晶,等.乳腺癌保乳术后同步加量IMRT前瞻性研究[J].中华放射肿瘤学杂志,2015,24(3):251-255.DOI:10.3760/cma.j.issn.1004-4221.2015.03.006 Peng R,Wang SL,Jin J,et al. A prospective study of intensity-modulated radiotherapy with integrated boost after breast conservative surgery in breast cancer patients[J].Chin J Radiat Oncol,2015,24(3):251-255.DOI:10.3760/cma.j.issn.1004-4221.2015.03.006 [11]Freedman GM,Anderson PR,Bleicher RJ,et al. Five-year local control in a phase Ⅱ study of hypofractionated intensity modulated radiation therapy with an incorporated boost for early stage breast cancer[J].Int J Radiat Oncol Biol Phys,2012,84(4):888-893.DOI:10.1016/j.ijrobp.2012.01.091 [12]Formenti SC,Gidea-Addeo D,Goldberg JD,et al. Phase Ⅰ-Ⅱ trial of prone acmelerated intensity modulated radiation therapy to the breast to optimally spare normal tissue[J].J Clin Oncol,2007,25(16):2236-2242.DOI:10.1200/JCO.2006.09.1041 [13]Chadha M,Vongtama D,Friedmann P,et al. Comparative acute toxicity from whole breast irradiation using 3-week acmelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer[J].Clin Breast Cancer,2012,12(1):57-62.DOI:10.1016/j.clbc.2011.09.002 [14]陈佳艺,蒋国梁,俞晓立,等.早期乳腺癌乳房保留治疗的疗效分析[J].中华放射肿瘤学杂志,2008,17(6):446-449.DOI:10.3321/j.issn:1004-4221.2008.06.008 Chen JY,Jiang GL,Yu XL,et al. Outcome of breast-conservative therapy for early-stage breast cancer:a retrospective analysis[J].Chin J Radiat Oncol,2008,17(6):446-449.DOI:10.3321/j.issn:1004-4221.2008.06.008 [15]Bantema-Joppe EJ,Van Der Laan HP,De Bock GH,et al. Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy:results on local control and survival[J].Radiother Oncol,2011,100(2):215-220.DOI:10.1016/j.radonc.2011.05.027 [16]Ciervide R,Dhage S,Guth A,et al. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after acmelerated breast radiotherapy[J].Int J Radiat Oncol Biol Phys,2012,83(2):e159-164.DOI:10.1016/j.ijrobp.2011.11.025 [17]McGale P,Darby SC,Hall P,et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden[J].Radiother Oncol,2011,100(2):167-175.DOI:10.1016/j.radonc.2011.06.016 [18]Darby SC,Ewertz M,McGale P,et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer[J].N Engl J Med,2013,368(11):987-998.DOI:10.1056/NEJMoa1209825.
2016, Vol. 25 
